Turn Therapeutics’ (TTRX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Turn Therapeutics (NASDAQ:TTRX) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $8.00 price objective on the stock.

Other analysts have also recently issued research reports about the company. Weiss Ratings assumed coverage on Turn Therapeutics in a research report on Monday, January 5th. They set a “sell (e-)” rating for the company. D Boral Capital upgraded shares of Turn Therapeutics to a “strong-buy” rating in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Turn Therapeutics Price Performance

Shares of Turn Therapeutics stock opened at $4.62 on Tuesday. Turn Therapeutics has a 1 year low of $2.57 and a 1 year high of $26.50. The stock’s 50 day moving average is $3.71. The firm has a market cap of $136.01 million and a P/E ratio of -66.00.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.07) earnings per share for the quarter.

Insider Activity

In related news, Director Arthur F. Golden bought 9,868 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were acquired at an average cost of $3.44 per share, with a total value of $33,945.92. Following the completion of the transaction, the director owned 60,602 shares of the company’s stock, valued at approximately $208,470.88. The trade was a 19.45% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Abraham Chesed bought 14,286 shares of the stock in a transaction that occurred on Thursday, October 23rd. The stock was bought at an average price of $4.60 per share, with a total value of $65,715.60. Following the completion of the acquisition, the insider owned 1,447,268 shares of the company’s stock, valued at $6,657,432.80. This trade represents a 1.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 52,136 shares of company stock valued at $183,463 in the last 90 days.

Hedge Funds Weigh In On Turn Therapeutics

A hedge fund recently bought a new stake in Turn Therapeutics stock. RVW Wealth LLC acquired a new position in shares of Turn Therapeutics Inc. (NASDAQ:TTRX) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 18,000 shares of the company’s stock, valued at approximately $71,000. RVW Wealth LLC owned about 0.06% of Turn Therapeutics as of its most recent SEC filing.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.